Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector

FEBS Letters

Volumn 579, Issue 7, 2005, Pages 1658-1664

  Babon, Aurélie ^a   Almunia, Christine ^a   Boccaccio, Claire ^b   Beaumelle, Bruno ^c   Gelb, Michael H ^d   Ménez, André ^a   Maillère, Bernard ^a   Abastado, Jean Pierre ^b   Salcedo, Margarita ^b   Gillet, Daniel ^a  

^a CEA SACLAY   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ DE MONTPELLIER   (France)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bee venom phospholipase A2; Cross presentation; Cytomegalovirus; Dendritic cell vaccine

Indexed keywords

BEE VENOM; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOLIPASE A2; PROTEASOME; RECOMBINANT PROTEIN; VIRUS PHOSPHOPROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; ENDOSOME; EX VIVO STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; INTERNALIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMBRANE BINDING; PRIORITY JOURNAL;

EID: 20044393833     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.02.019     Document Type: Article

References (36)

1. L.D. Cranmer, K.T. Trevor, and E.M. Hersh Clinical applications of dendritic cell vaccination in the treatment of cancer Cancer Immunol. Immunother. 53 2004 275 306
2. E.G. Engleman Dendritic cell-based cancer immunotherapy Semin. Oncol. 30 2003 23 29
3. A. Kugler, G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C.A. Muller, V. Becker, A.J. Gross, B. Hemmerlein, L. Kanz, G.A. Muller, and R.H. Ringert Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids [see comments] Nat. Med. 6 2000 332 336
4. W. Herr, E. Ranieri, W. Olson, H. Zarour, L. Gesualdo, and W.J. Storkus Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses Blood 96 2000 1857 1864
5. G. Arrode, C. Boccaccio, J. Lule, S. Allart, N. Moinard, J.P. Abastado, A. Alam, and C. Davrinche Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells J. Virol. 74 2000 10018 10024
6. Y. Tamura, P. Peng, K. Liu, M. Daou, and P.K. Srivastava Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations Science 278 1997 117 120
7. D. Boczkowski, S.K. Nair, J.H. Nam, H.K. Lyerly, and E. Gilboa Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells Cancer Res. 60 2000 1028 1034
8. B. Ludewig, A.F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R.M. Zinkernagel Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease J. Exp. Med. 191 2000 795 804
9. S. Hacein-Bey-Abina, C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J.L. Villeval, C.C. Fraser, M. Cavazzana-Calvo, and A. Fischer A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N. Engl. J. Med. 348 2003 255 256
10. R.H. Simon, J.F. Engelhardt, Y. Yang, M. Zepeda, S. Weber-Pendleton, M. Grossman, and J.M. Wilson Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study Hum. Gene Ther. 4 1993 771 780
11. M.K. Jain, B.Z. Yu, J. Rogers, G.N. Ranadive, and O.G. Berg Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors Biochemistry 30 1991 7306 7317
12. R.R. Annand, M. Kontoyianni, J.E. Penzotti, T. Dudler, T.P. Lybrand, and M.H. Gelb Active site of bee venom phospholipase A2: the role of histidine-34, aspartate-64 and tyrosine-87 Biochemistry 35 1996 4591 4601
13. A. Solache, C.L. Morgan, A.I. Dodi, C. Morte, I. Scott, C. Baboonian, B. Zal, J. Goldman, J.E. Grundy, and J.A. Madrigal Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus J. Immunol. 163 1999 5512 5518
14. M.R. Wills, A.J. Carmichael, K. Mynard, X. Jin, M.P. Weekes, B. Plachter, and J.G. Sissons The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL J. Virol. 70 1996 7569 7579
15. C. Kyritsis, S. Gorbulev, S. Hutschenreiter, K. Pawlitschko, R. Abele, and R. Tampe Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6 J. Biol. Chem. 276 2001 48031 48039
16. T. Dudler, W.Q. Chen, S. Wang, T. Schneider, R.R. Annand, R.O. Dempcy, R. Crameri, M. Gmachl, M. Suter, and M.H. Gelb High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2 Biochim. Biophys. Acta 1165 1992 201 210
17. C. Buhot, A. Chenal, A. Sanson, S. Pouvelle-Moratille, M.H. Gelb, A. Menez, D. Gillet, and B. Maillere Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity Protein Sci. 13 2004 2970 2978
18. B. Goxe, N. Latour, M. Chokri, J.P. Abastado, and M. Salcedo Simplified method to generate large quantities of dendritic cells suitable for clinical applications Immunol. Invest. 29 2000 319 336
19. C. Boccaccio, S. Jacod, A. Kaiser, A. Boyer, J.P. Abastado, and A. Nardin Identification of a clinical-grade maturation factor for dendritic cells J. Immunother. 25 2002 88 96
20. J. Morlon-Guyot, M. Helmy, S. Lombard-Frasca, D. Pignol, G. Pieroni, and B. Beaumelle Identification of the ricin lipase site and implication in cytotoxicity J. Biol. Chem. 278 2003 17006 17011
21. A. Kaiser, N. Bercovici, J.P. Abastado, and A. Nardin Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation Eur. J. Immunol. 33 2003 162 171
22. J. Gruenberg, and F.R. Maxfield Membrane transport in the endocytic pathway Curr. Opin. Cell Biol. 7 1995 552 563
23. A.W. van Weert, K.W. Dunn, H.J. Geuze, F.R. Maxfield, and W. Stoorvogel Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump J. Cell Biol. 130 1995 821 834
24. A. Craiu, M. Gaczynska, T. Akopian, C.F. Gramm, G. Fenteany, A.L. Goldberg, and K.L. Rock Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation J. Biol. Chem. 272 1997 13437 13445
25. S. Gnjatic, E. Jager, W. Chen, N.K. Altorki, M. Matsuo, S.Y. Lee, Q. Chen, Y. Nagata, D. Atanackovic, Y.T. Chen, G. Ritter, J. Cebon, A. Knuth, and L.J. Old CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients Proc. Natl Acad. Sci. USA 99 2002 11813 11818
26. C.C. Norbury J.C. Solheim Methods in molecular biology: antigen processing and presentation protocols vol. 156 2000 Humana Press Inc. Totowa, NJ 1 16
27. B. Maillere, G. Mourier, M. Herve, and A. Menez Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC- complexed peptides Mol. Immunol. 32 1995 1377 1385
28. W.R. Heath, and F.R. Carbone Cross-presentation in viral immunity and self-tolerance Nat. Rev. Immunol. 1 2001 126 134
29. M. Houde, S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M.F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins Phagosomes are competent organelles for antigen cross-presentation Nature 425 2003 402 406
30. P. Guermonprez, L. Saveanu, M. Kleijmeer, J. Davoust, P. Van Endert, and S. Amigorena ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells Nature 425 2003 397 402
31. D.C. Smith, J.M. Lord, L.M. Roberts, E. Tartour, and L. Johannes 1st class ticket to class I: protein toxins as pathfinders for antigen presentation Traffic 3 2002 697 704
32. D.C. Smith, A. Gallimore, E. Jones, B. Roberts, J.M. Lord, E. Deeks, V. Cerundolo, and L.M. Roberts Exogenous peptides delivered by ricin require processing by signal peptidase for transporter associated with antigen processing-independent MHC class I-restricted presentation J. Immunol. 169 2002 99 107
33. F. Mallard, C. Antony, D. Tenza, J. Salamero, B. Goud, and L. Johannes Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of shiga toxin B-fragment transport J. Cell Biol. 143 1998 973 990
34. N.H. Carbonetti, T.J. Irish, C.H. Chen, C.B. O'Connell, G.A. Hadley, U. McNamara, R.G. Tuskan, and G.K. Lewis Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway Infect. Immun. 67 1999 602 607
35. T. Serwold, F. Gonzalez, J. Kim, R. Jacob, and N. Shastri ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum Nature 419 2002 480 483
36. L. Perrin-Cocon, S. Agaugue, F. Coutant, A. Masurel, S. Bezzine, G. Lambeau, P. Andre, and V. Lotteau Secretory phospholipase A2 induces dendritic cell maturation Eur. J. Immunol. 34 2004 2293 2302